How the Endocannabinoid System Drives Both Food Craving and Fat Storage

The endocannabinoid system both stimulates appetite by increasing food craving and enjoyment and promotes fat storage, making CB1 blockers a potential class of anti-obesity drugs.

Kirkham, Tim·Journal of neuroendocrinology·2008·Moderate EvidenceReview
RTHC-00317ReviewModerate Evidence2008RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

This brief review outlined how the endocannabinoid system drives overeating through two complementary mechanisms.

First, endocannabinoids acting at CB1 receptors in the brain increase appetite by enhancing both food craving (wanting) and food enjoyment (liking). This explains the well-known "munchies" effect of cannabis.

Second, the endocannabinoid system promotes energy storage as fat in adipose (fat) tissue, meaning it doesn't just increase food intake but also directs where that energy goes.

These dual actions, increasing intake and promoting storage, raised the possibility that CB1 receptor blockers could address obesity from both directions: reducing appetite and decreasing fat deposition.

Key Numbers

Endocannabinoids activate CB1 receptors in brain (appetite) and peripheral tissues (fat storage). CB1 antagonists were identified as potential anti-obesity agents.

How They Did This

Brief narrative review or editorial summarizing the current understanding of endocannabinoid system involvement in appetite regulation and energy storage.

Why This Research Matters

Understanding that the endocannabinoid system drives both overconsumption and fat storage explained why cannabis users often experience intense food cravings and why the CB1 blocker rimonabant showed weight loss effects in clinical trials.

The Bigger Picture

While the specific drug rimonabant was later withdrawn due to psychiatric side effects, the concept of endocannabinoid-driven appetite and fat storage has remained central to obesity research. Newer approaches aim to block peripheral CB1 receptors (in fat tissue) while sparing brain CB1 receptors to avoid psychiatric effects.

What This Study Doesn't Tell Us

This is a brief editorial rather than a systematic review. It summarizes the concept without detailed evidence assessment.

Questions This Raises

  • ?Can peripherally restricted CB1 antagonists reduce fat storage without affecting brain appetite circuits?
  • ?Do chronically obese individuals have elevated endocannabinoid tone?

Trust & Context

Key Stat:
Endocannabinoids drive both appetite (brain CB1) and fat storage (peripheral CB1)
Evidence Grade:
This is a brief editorial or commentary summarizing established concepts rather than presenting new data.
Study Age:
Published in 2008, around the time rimonabant was being withdrawn from European markets. Peripheral CB1 antagonists are still in development.
Original Title:
Endocannabinoids and the neurochemistry of gluttony.
Published In:
Journal of neuroendocrinology, 20(9), 1099-100 (2008)
Authors:
Kirkham, Tim
Database ID:
RTHC-00317

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why does cannabis cause "the munchies"?

Cannabis activates CB1 receptors in brain regions that control appetite, increasing both food craving (wanting food) and food enjoyment (how good it tastes). This makes you want to eat and makes food seem more rewarding.

What happened to CB1-blocking weight loss drugs?

Rimonabant, a CB1 blocker, was approved in Europe for weight loss in 2006 but withdrawn in 2008 due to psychiatric side effects (depression, suicidal thoughts). Researchers are now developing versions that only block CB1 in fat tissue, not the brain.

Read More on RethinkTHC

Cite This Study

RTHC-00317·https://rethinkthc.com/research/RTHC-00317

APA

Kirkham, Tim. (2008). Endocannabinoids and the neurochemistry of gluttony.. Journal of neuroendocrinology, 20(9), 1099-100. https://doi.org/10.1111/j.1365-2826.2008.01762.x

MLA

Kirkham, Tim. "Endocannabinoids and the neurochemistry of gluttony.." Journal of neuroendocrinology, 2008. https://doi.org/10.1111/j.1365-2826.2008.01762.x

RethinkTHC

RethinkTHC Research Database. "Endocannabinoids and the neurochemistry of gluttony." RTHC-00317. Retrieved from https://rethinkthc.com/research/kirkham-2008-endocannabinoids-and-the-neurochemistry

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.